Platelet-activating factor is crucial in psoralen and ultraviolet A-induced immune suppression, inflammation, and apoptosis

American Journal of Pathology

Volumn 169, Issue 3, 2006, Pages 795-805

  Wolf, Peter ^a,b   Nghiem, Dat X ^b,c   Walterscheid, Jeffrey P ^b,c   Byrne, Scott ^b   Matsumura, Yumi ^b   Matsumura, Yasuhiro ^b   Bucana, Cora ^b   Ananthaswamy, Honnavara N ^b,c   Ullrich, Stephen E ^b,c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Program in Biomathematics and Biostatistics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 2,4,6 TRIMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID METHYL 2 PHENYLTHIOETHYL ESTER; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CYCLOOXYGENASE 2 INHIBITOR; INTERLEUKIN 10; PROTEIN P53; PSORALEN; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG INHIBITION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; PUVA; RADIATION DOSE; SKIN INFLAMMATION; T CELL LYMPHOMA; ULTRAVIOLET A RADIATION;

EID: 33748784361     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.060079     Document Type: Article

References (54)

1. Hönigsmann H, Szeimies RM, Knobler R, Fitzpatrick TB, Pathak MA, Wolff K: Photochemotherapy and photodynamic therapy. Fitzpatrick's Dermatology in General Medicine. Edited by Freedberg IM, Eizen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI. New York, McGraw-Hill, 2003, pp 2477-2493
2. Santamaria AB, Davis DW, Nghiem DX, McConkey DJ, Ullrich SE, Kapoor M, Lozano G, Ananthaswamy HN: p53 and Fas ligand are required for psoralen and UVA-induced apoptosis in mouse epidermal cells. Cell Death Differ 2002, 9:549-560
3. Vallat VP, Gilleaudeau P, Battat L, Wolfe J, Nabeya R, Heftler N, Hodak E, Gottlieb AB, Krueger JG: PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 1994, 180:283-296
4. Caffieri S: Furocoumarin photolysis: chemical and biological aspects. Photochem Photobiol Sci 2002, 1:149-157
5. Zarebska Z, Zielinska J, Zhukov I, Maslinski W: Apoptosis induced by membrane damage in human lymphocytes; effects of arachidonic acid and its photoproducts. Acta Biochim Pol 2005, 52:179-194
6. Walterscheid JP, Ullrich SE, Nghiem DX: Platelet-activating factor, a molecular sensor for cellular damage, activates systemic immune suppression. J Exp Med 2002, 195:171-179
7. Barber LA, Spandau DF, Rathman SC, Murphy RC, Johnson CA, Kelley SW, Hurwitz SA, Travers JB: Expression of the platelet-activating factor receptor results in enhanced ultraviolet B radiation-induced apoptosis in a human epidermal cell line. J Biol Chem 1998, 273:18891-18897
8. Gresham A, Masferrer J, Chen X, Leal-Khouri S, Pentland AP: Increased synthesis of high-molecular-weight cPLA2 mediates early UV-induced PGE2 in human skin. Am J Physiol 1996, 270:C1037-C1050
9. Lewis MS, Whatley RE, Cain P, McIntyre TM, Prescott SM, Zimmerman GA: Hydrogen peroxide stimulates the synthesis of platelet-activating factor by endothelium and induces endothelial cell-dependent neutrophil adhesion. J Clin Invest 1988, 82:2045-2055
10. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, Isakson P: Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994, 91:12013-12017
11. Nghiem DX, Kazimi N, Mitchell DL, Vink AA, Ananthaswamy HN, Kripke ML, Ullrich SE: Mechanisms underlying the suppression of established immune responses by ultraviolet radiation. J Invest Dermatol 2002, 119:600-608
12. Wolf P, Cox P, Yarosh DB, Kripke ML: Sunscreens and T4N5 liposomes differ in their ability to protect against ultraviolet-induced sunburn cell formation, alterations of dendritic epidermal cells, and local suppression of contact hypersensitivity. J Invest Dermatol 1995, 104:287-292
13. Ouhtit A, Muller HK, Davis DW, Ullrich SE, McConkey D, Ananthaswamy HN: Temporal events in skin injury and the early adaptive responses in ultraviolet-irradiated mouse skin. Am J Pathol 2000, 156:201-207
14. Legat FJ, Hofer A, Quehenberger F, Kahofer P, Kerl H, Wolf P: Reduction of treatment frequency and UVA dose does not substantially compromise the antipsoriatic effect of oral psoralen-UVA. J Am Acad Dermatol 2004, 51:746-754
15. Pei Y, Barber LA, Murphy RC, Johnson CA, Kelley SW, Dy LC, Fertel RH, Nguyen TM, Williams DA, Travers JB: Activation of the epidermal platelet-activating factor receptor results in cytokine and cyclooxygenase-2 biosynthesis. J Immunol 1998, 161:1954-1961
16. Ishii S, Shimizu T: Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog Lipid Res 2000, 39:41-82
17. Rivas JM, Ullrich SE: Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes. An essential role for keratinocyte-derived IL-10. J Immunol 1992, 149:3865-3871
18. Shreedhar V, Giese T, Sung VW, Ullrich SE: A cytokine cascade including prostaglandin E2, IL-4, and IL-10 is responsible for UV-induced systemic immune suppression. J Immunol 1998, 160:3783-3789
19. Ullrich SE, Lyons HJ: Mechanisms involved in the immunotoxicity induced by dermal application of JP-8 jet fuel. Toxicol Sci 2000, 58:290-298
20. Ramos G, Kazimi N, Nghiem DX, Walterscheid JP, Ullrich SE: Platelet activating factor receptor binding plays a critical role in jet fuel-induced immune suppression. Toxicol Appl Pharmacol 2004, 195:331-338
21. Frank S, Caffieri S, Raffaelli A, Vedaldi D, Dall'Acqua F: Characterization of psoralen-oleic acid cycloadducts and their possible involvement in membrane photodamage. J Photochem Photobiol B 1998, 44:39-44
22. Anthony FA, Laboda HM, Costlow ME: Psoralen-fatty acid adducts activate melanocyte protein kinase C: a proposed mechanism for melanogenesis induced by 8-methoxypsoralen and ultraviolet A light. Photodermatol Photoimmunol Photomed 1997, 13:9-16
23. Tuominen M, Bohlin L, Rolfsen W: Effects of calaguala and an active principle, adenosine, on platelet activating factor. Planta Med 1992, 58:306-310
24. Gonzalez S, Pathak MA, Cuevas J, Villarrubia VG, Fitzpatrick TB: Topical or oral administration with an extract of Polypodium leucotomos prevents acute sunburn and psoralen-induced phototoxic reactions as well as depletion of Langerhans cells in human skin. Photodermatol Photoimmunol Photomed 1997, 13:50-60
25. Shyong EQ, Lu Y, Lazinsky A, Saladi RN, Phelps RG, Austin LM, Lebwohl M, Wei H: Effects of the isoflavone 4′,5,7-trihydroxyisoflavone (genistein) on psoralen plus ultraviolet A radiation (PUVA)-induced photodamage. Carcinogenesis 2002, 23:317-321
26. Bulavin DV, Higashimoto Y, Popoff IJ, Gaarde WA, Basrur V, Potapova O, Appella E, Fornace Jr AJ: Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature 2001, 411:102-107
27. Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ: cPLA2 is phosphorylated and activated by MAP kinase. Cell 1993, 72:269-278
28. Marques M, Pei Y, Southall MD, Johnston JM, Arai H, Aoki J, Inoue T, Seltmann H, Zouboulis CC, Travers JB: Identification of platelet-activating factor acetylhydrolase II in human skin. J Invest Dermatol 2002, 119:913-919
29. Reich K, Garbe C, Blaschke V, Maurer C, Middel P, Westphal G, Lippert U, Neumann C: Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol 2001, 116:319-329
30. Countryman NB, Pei Y, Yi Q, Spandau DF, Travers JB: Evidence for involvement of the epidermal platelet-activating factor receptor in ultraviolet-B-radiation-induced interleukin-8 production. J Invest Dermatol 2000, 115:267-272
31. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, van der Zee R, Biedermann T, Prinz J, Mack M, Mrowietz U, Christophers E, Schlondorff D, Plewig G, Sander CA, Rocken M: Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003, 9:40-46
32. Nickoloff BJ, Nestle FO: Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004, 113:1664-1675
33. Zhao JF, Zhang YJ, Kubilus J, Jin XH, Santella RM, Athar M, Wang ZY, Bickers DR: Reconstituted 3-dimensional human skin as a novel in vitro model for studies of Carcinogenesis. Biochem Biophys Res Commun 1999, 254:49-53
34. Hannuksela-Svahn A, Paakko P, Autio P, Reunala T, Karvonen J, Vahakangas K: Expression of p53 protein before and after PUVA treatment in psoriasis. Acta Dermatol Venereol 1999, 79:195-199
35. Johnson R, Staiano-Coico L, Austin L, Cardinale I, Nabeya-Tsukifuji R, Krueger JG: PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes. Photochem Photobiol 1996, 63:566-571
36. Yoo EK, Rook AH, Elenitsas R, Gasparro FP, Vowels BR: Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action. J Invest Dermatol 1996, 107:235-242
37. Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, Ubriani R, Vittorio CC, Junkins-Hopkins JM, Wysocka M, Rook AH: Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005, 115:798-812
38. Gilhar A, Yaniv R, Assy B, Serafimovich S, Ullmann Y, Kalish RS: Fas pulls the trigger on psoriasis. Am J Pathol 2006, 168:170-175
39. Brewer C, Bonin F, Bullock P, Nault MC, Morin J, Imbeault S, Shen TY, Franks DJ, Bennett SA: Platelet activating factor-induced apoptosis is inhibited by ectopic expression of the platelet activating factor G-protein coupled receptor. J Neurochem 2002, 82:1502-1511
40. Southall MD, Isenberg JS, Nakshatri H, Yi Q, Pei Y, Spandau DF, Travers JB: The platelet-activating factor receptor protects epidermal cells from tumor necrosis factor (TNF) alpha and TNF-related apoptosis-inducing ligand-induced apoptosis through an NF-kappa B-dependent process. J Biol Chem 2001, 276:45548-45554
41. Fazal N, Al-Ghoul WM, Choudhry MA, Sayeed MM: PAF receptor antagonist modulates neutrophil responses with thermal injury in vivo. Am J Physiol 2001, 281:C1310-C1317
42. Baltas E, Trach V, Dobozy A, Kemeny L: Platelet-activating factor antagonist WEB 2086 inhibits ultraviolet-B radiation-induced dermatitis in the human skin. Skin Pharmacol Appl Skin Physiol 2003, 16:259-262
43. Voss A, Leverkus M, Brocker EB, Goebeler M: Topical psoralen photochemotherapy with lethal outcome. Arch Dermatol 2001, 137:383
44. Wackernagel A, Hofer A, Legat F, Kerl H, Wolf P: Efficacy of 8-methoxypsoralen versus 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides. Br J Dermatol 2006, 154:519-523
45. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, Krueger JG: Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995, 1:442-447
46. Gottlieb AB: Novel immunotherapies for psoriasis: clinical research delivers new hope for patients and scientific advances. J Investig Dermatol Symp Proc 2004, 9:79-83
47. Villadsen LS, Schuurman J, Beurskens F, Dam TN, Dagnaes-Hansen F, Skov L, Rygaard J, Voorhorst-Ogink MM, Gerritsen AF, van Dijk MA, Parren PW, Baadsgaard O, van de Winkel JG: Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003, 112:1571-1580
48. Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K, Itami S, Nickoloff BJ, DiGiovanni J: Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005, 11:43-49
49. Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D, Scheuch H, Angel P, Tschachler E, Wagner EF: Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005, 437:369-375
50. Voskas D, Jones N, Van Slyke P, Sturk C, Chang W, Haninec A, Babichev YO, Tran J, Master Z, Chen S, Ward N, Cruz M, Jones J, Kerbel RS, Jothy S, Dagnino L, Arbiser J, Klement G, Dumont DJ: A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. Am J Pathol 2005, 166:843-855
51. Bhagavathula N, Nerusu KC, Fisher GJ, Liu G, Thakur AB, Gemmell L, Kumar S, Xu ZH, Hinton P, Tsurushita N, Landolfi NF, Voorhees JJ, Varani J: Amphiregulin and epidermal hyperplasia: amphiregulin is required to maintain the psoriatic phenotype of human skin grafts on severe combined immunodeficient mice. Am J Pathol 2005, 166:1009-1016
52. Miyauchi-Hashimoto H, Okamoto H, Sugihara A, Horio T: Therapeutic and prophylactic effects of PUVA photochemotherapy on atopic dermatitis-like lesions in NC/Nga mice. Photodermatol Photoimmunol Photomed 2005, 21:125-130
53. Stern RS, Bolshakov S, Nataraj AJ, Ananthaswamy HN: p53 mutation in nonmelanoma skin cancers occurring in psoralen ultraviolet a-treated patients: evidence for heterogeneity and field cancerization. J Invest Dermatol 2002, 119:522-526
54. Wolf P, Kreimer-Erlacher H, Seidl H, Back B, Soyer HP, Kerl H: The ultraviolet fingerprint dominates the mutational spectrum of the p53 and Ha-ras genes in psoralen + ultraviolet A keratoses from psoriasis patients. J Invest Dermatol 2004, 122:190-200